# Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC

> **NCT07561983** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan Cancer Hospital and Research Institute** · enrollment: 39 (estimated)

## Conditions studied

- Unresectable Stage III Non-small Cell Lung Cancer
- Tislelizumab
- Chemotherapy
- Chemoembolization, Therapeutic
- Conversion Therapy

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Intravenous Chemotherapy
- **PROCEDURE:** Bronchial Artery Chemoembolization (BACE)

## Key facts

- **NCT ID:** NCT07561983
- **Lead sponsor:** Sichuan Cancer Hospital and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07561983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07561983, "Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07561983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*